SCHEMBL164540

SCHEMBL164540

CCNC(=O)c1cccnc1[O]

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHIA Q9BZP6 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.48
KMT2A Q03164 1/20 0.48
P2RX7 Q99572 1/20 0.47
HCRTR1 O43613 2/20 0.45
HPGD P15428 3/20 0.45
RIPK1 Q13546 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
LMNA P02545 4/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NSD2 O96028 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162691 0.87 TSHR (0.51) L3MBTL1KMT2AP2RX7HCRTR1HPGD
SCHEMBL161560 0.84 HTT (0.66) L3MBTL1KMT2AHCRTR1HPGDADRA1D
SCHEMBL6653582 0.83 CHIA (0.56) CHIAL3MBTL1KMT2AP2RX7HPGD
SCHEMBL5418289 0.83 P2RX7 (0.70) CHIAL3MBTL1KMT2AP2RX7HPGD
SCHEMBL164226 0.82 POLB (0.50) KMT2AP2RX7HPGDADRA1DADRA1A
SCHEMBL13687262 0.81 NAPRT (0.56) CHIAL3MBTL1KMT2AP2RX7HPGD
SCHEMBL13702282 0.81 SMN1; SMN2 (0.59) CHIAKMT2AHPGDLMNAHTT
SCHEMBL30267808 0.81 CHIA (0.55) CHIAL3MBTL1KMT2AP2RX7HPGD
SCHEMBL13973141 0.81 PRKCI (0.58) CHIAL3MBTL1KMT2AP2RX7HPGD
SCHEMBL29520153 0.81 PRKCI (0.58) CHIAL3MBTL1KMT2AP2RX7HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 CHIA 3787/4885L3MBTL1 1654/4885KMT2A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.